2023
164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
LAFFEL L, DANNE T, TAMBORLANE W, KLINGENSMITH G, NEUBACHER D, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S. 164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo. Diabetes 2023, 72 DOI: 10.2337/db23-164-lb.Peer-Reviewed Original ResearchHbA1c <Increasing prevalence of childhood overweightGlycemic controlPrevalence of childhood overweightSafety of empagliflozinLinagliptin 5 mgClinically meaningful responseYouth-onset T2DOnset of complicationsBeta-cell functionPost hoc analysisEmpagliflozin groupClinical courseFPG levelsChildhood overweightSGLT2 inhibitorsEmpagliflozinYouth-onsetPlaceboHbA1c changeMeaningful responseHbA1cHigher HbA1cHoc analysisIncreased prevalence
2019
Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec
2002
Prevalence of Impaired Glucose Tolerance among Children and Adolescents with Marked Obesity
Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of Impaired Glucose Tolerance among Children and Adolescents with Marked Obesity. New England Journal Of Medicine 2002, 346: 802-810. PMID: 11893791, DOI: 10.1056/nejmoa012578.Peer-Reviewed Original ResearchConceptsImpaired glucose toleranceType 2 diabetesC-peptide levelsGlucose toleranceGlucose tolerance testBeta-cell functionInsulin resistanceObese childrenInsulin levelsObese adolescentsGlucose levelsTwo-hour oral glucose tolerance testImpaired oral glucose toleranceOvert type 2 diabetesOral glucose tolerance testHomeostatic model assessmentOral glucose toleranceBody mass indexLevels of proinsulinBeta-cell failureIngestion of glucoseRatio of proinsulinSevere obesityMarked obesityChildhood obesity
1996
Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children
Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV. Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children. Diabetologia 1996, 39: 1489-1497. PMID: 8960831, DOI: 10.1007/s001250050603.Peer-Reviewed Original ResearchConceptsObese groupHyperglycaemic clampInsulin resistanceObese preadolescentsInsulin actionGlucose-stimulated insulin levelsHigher insulin infusion ratesNon-oxidative glucose metabolismGlucose uptakeDuration of obesityGroup of obeseNon-obese subjectsBeta-cell functionDevelopment of obesityEuglycaemic hyperinsulinaemic clampSevere insulin resistanceInsulin infusion rateCross-sectional analysisOnset of pubertyAbility of insulinSevere obesityObese adultsObese childrenObese subjectsInsulin levels